This randomised, placebo-controlled, quadruple-masked trial (n=112) will investigate whether the antidepressant effects of DMT (2 mg/min over 20 minutes) in patients with major depressive disorder (MDD) depend on the subjective psychedelic experience, by comparing DMT with and without sedation using propofol.
Conducted by University Hospital Basel, this 2×2 factorial Phase II study will assess the biological versus experiential contributions to DMT’s antidepressant effects. Participants will be randomly assigned to receive either DMT or placebo, with or without concurrent sedation using propofol. Propofol is used here to mask the psychedelic experience, enabling researchers to isolate DMT’s potential neurobiological effects—such as those linked to neuroplasticity or anti-inflammatory pathways—independent of the altered state of consciousness it typically produces.
All participants must have moderate to severe MDD (defined as MADRS score >20) and no history of psychotic or bipolar disorders. The primary outcome is the change in depressive symptoms from baseline to 14 days after treatment, measured using the Montgomery–Åsberg Depression Rating Scale (MADRS). This innovative trial could clarify whether psychedelics exert their therapeutic effects through subjective experience or underlying biological mechanisms.
Trial Details
Trial Number
Sponsors & Collaborators
University of BaselThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.